Basics Intellia Therapeutics, Inc. Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. IPO Date: May 6, 2016 Sector: Healthcare Industry: Biotech Market Cap: $965.92M Activated in VL: True Average Daily Range Avg Daily Range: $1.15 | 3.18% Avg Daily Range (30 D): $0.32 | 3.92% Avg Daily Range (90 D): $0.36 | 4.10% Institutional Daily Volume Avg Daily Volume: .97M Avg Daily Volume (30 D): 3.56M Avg Daily Volume (90 D): 3.21M Trade Size Avg Trade Size (Sh.): 71 Avg Trade Size (Sh.) (30 D): 108 Avg Trade Size (Sh.) (90 D): 98 Institutional Trades Total Inst.Trades: 4,267 Avg Inst. Trade: $3M Avg Inst. Trade (30 D): $2.1M Avg Inst. Trade (90 D): $2.2M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.86M Avg Closing Trade (30 D): $2.58M Avg Closing Trade (90 D): $2.91M Avg Closing Volume: 137.32K         News May 23, 2025 @ 1:29 PM Analysts Think These Stocks Could More Than Double... Source: Marketbeat.Com May 23, 2025 @ 1:00 AM INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Inv... Source: N/A May 18, 2025 @ 11:25 AM Intellia Announces Positive Two-Year Follow-Up Dat... Source: N/A May 6, 2025 @ 5:00 PM Angioedema Clinical Trial Pipeline Analysis Demons... Source: Delveinsight Apr 30, 2025 @ 2:15 PM Cathie Wood Goes Bargain Hunting: 3 Stocks She Jus... Source: Rick Munarriz Financials   TTM Q3 2024 Q2 2024 Basic EPS $-1.1 $-1.34 $-1.52 Diluted EPS $-1.1 $-1.34 $-1.52 Revenue $ 16.63M $ 9.11M $ 6.96M Gross Profit $ $ $ Net Income / Loss $ -114.33M $ -135.71M $ -146.98M Operating Income / Loss $ -120.81M $ -144.77M $ -139.04M Cost of Revenue $ $ $ Net Cash Flow $ M $ -10.35M $ -41.13M PE Ratio